Fareha Malik, MD
Child & Adolescent Psychiatry · Elgin, ILNPI 1780692038
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Axsome Therapeutics, Inc. accounts for 70.3% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $35,212, more than ten times the $68 reported in 2019. Among child & adolescent psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $192.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$40K
- Otsuka America Pharmaceutical, Inc.$8K
- AbbVie$6K
- Johnson & Johnson$875
- Teva Pharmaceuticals USA, Inc.$409
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$351
- plus $2K from 20 others
Across 102 payments — averaging $3847.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$303K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$33K
- AbbVie$25K
- Supernus Pharmaceuticals, Inc.$16K
- Purdue Pharma L.p.$9K
- Bioxcel Therapeutics, Inc.$7K
What the payments were for
- Consulting fees$16,25029%
- Speaking & faculty fees$32,22157%
- Travel & lodging$1,6723%
- Food & beverage$6,46011%
- Education$2120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 58 | $39,916 |
| Otsuka America Pharmaceutical, Inc. | 33 | $7,981 |
| AbbVie(2 entities) | 54 | $5,697 |
| Johnson & Johnson | 41 | $875 |
| Teva Pharmaceuticals USA, Inc. | 12 | $409 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $351 |
| Corium, LLC | 18 | $236 |
| Supernus Pharmaceuticals, Inc. | 11 | $222 |
| Neurocrine Biosciences, Inc. | 8 | $160 |
| Tris Pharma Inc | 9 | $158 |
| Vanda Pharmaceuticals Inc. | 2 | $146 |
| Lundbeck LLC | 7 | $125 |
| Alkermes, Inc. | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Bausch Health US, LLC | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Noven Therapeutics, LLC | 2 | $35 |
| Neuronetics, Inc. | 2 | $28 |
| Neos Therapeutics, LP | 1 | $23 |
| Tempus AI, Inc | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Biogen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,815 in reported general payments places this provider in the 95th percentile of 124 child & adolescent psychiatry providers in Illinois.
See all child & adolescent psychiatry providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 155 | $200,006 |
| AustedoDeutetrabenazine | 19 | $174,099 |
| VraylarCariprazine Hcl | 13 | $18,649 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,296 |
| Aripiprazole | 86 | $6,507 |
| Desipramine Hcl | 12 | $2,648 |
| Bupropion XlBupropion Hcl | 89 | $2,536 |
| Trazodone Hcl | 125 | $1,879 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $1,747 |
| Duloxetine Hcl | 88 | $1,731 |
| Buspirone Hcl | 72 | $1,320 |
| Lisdexamfetamine Dimesylate | 11 | $1,258 |
| Escitalopram Oxalate | 102 | $1,106 |
| Quetiapine Fumarate | 79 | $972 |
| Clonazepam | 135 | $860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $875 | $200,006155 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $409 | $174,09919 claims |
| AbbVieVraylar | $5,697 | $18,64913 claims |
| Axsome Therapeutics, Inc.Auvelity | $39,916 | $13,29612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 124 child & adolescent psychiatry providers in Illinois.
Other child & adolescent psychiatry in Elgin
- Gregory TeasHoffman Estates$36K
- Martins AdeoyeOrland Park$10K
- Daniel MartinezLombard$8K
- Khalid ArshadKankakee$8K
- Talat GhausHinsdale$6K
- Walter PedemonteOak Park$5K
- Shazia TayyabLibertyville$5K
- Bradley PechterMelrose Park$5K
- Birju PatelKenilworth$5K
- Ing LamOrland Park$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.